 |
 |
Michael J. Fox Foundation Announces Funding for Ceregene Phase-1 Gene Therapy Clinical Trial 11/28/2005 U.S. Newswire (press release) - Washington,DC,USA NEW YORK, Nov. 28 /U.S. Newswire/ -- The Michael J. Fox Foundation for Parkinson’s Research (MJFF) today announced a three-year grant of approximately $740,000 to Ceregene, Inc., a San Diego-based biotechnology company. The grant will help fund Ceregene’s Phase I clinical study of CERE-120, a novel gene therapy product that has shown potential in pre-clinical testing to slow or stop the progression of Parkinson’s disease by using a vector to deliver neurturin, a potent nervous system growth factor. full text at: http://releases.usnewswire.com/GetRelease.asp?id=57198 ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn